EFFECT OF BRAHMISOHALADI SIROLEPA IN CHILDREN WITH AUTISM SPECTRUM DISORDERS by Anirudhan, *Roshni & Nalinakshan, A
ISSN: 2322 - 0902 (P) 
ISSN: 2322 - 0910 (O) 
     IJAPR | December 2017 | Vol 5 | Issue 12  39 
International Journal of Ayurveda  
and Pharma Research 
 
Research Article 
 
EFFECT OF BRAHMISOHALADI SIROLEPA IN CHILDREN WITH AUTISM SPECTRUM DISORDERS 
Roshni Anirudhan1*, A Nalinakshan2 
*1Professor & Head of Department of Kaumarabhrithya, Government Ayurveda College, Thiruvananthapuram, 
Kerala, India. 
2Pro-Vice Chancellor, Kerala University of Health Sciences, Thrissur, Kerala, India. 
ABSTRACT 
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by impairment 
in social interaction and communication with restricted interests and repetitive behaviour. The 
prevalence of ASD has shown an alarming increase in the recent decades ending up to 1 in 90 
children. In spite of enormous researches in contemporary medical field, no medicaments have 
proved to be effective in improving their social behaviour. In Ayurveda, ASD comes under the 
category of Unmada involving derangement of all the three Doshas (Vishama sannipatha) with 
predominance of Vata & Pitha. Child friendly and effective procedure based therapy in the form of 
Sirolepa (application of medicated paste on scalp) is being tried in children with ASD between 3 
and 12 years selected from the outpatient cases of Dept. Of Kaumarabhrithya, Government 
Ayurveda College, Thiruvananthapuram. The present study empirically analysis the efficacy of 
Sirolepa with Brahmisohaladi with its classical reference in Arogyakalpadruma in the context of 
Unmada. Children with ASD satisfying the DSM V criteria and having a CARS score above 30 were 
selected for the study having duration of 28 days. There was an observable improvement in eye 
contact, attention span and sleep pattern with a marked reduction in hyperactivity. All of the 
children included in the study were receiving speech as well as psycho therapies and appropriate 
dietary advice throughout the treatment course. The clinical observation was supported by CARS 
(Childhood Autism Rating Scale) & ATEC (Autism Treatment Evaluation Checklist) recorded as 
pre- post evaluation. The changes in CARS and ATEC score were highly significant at 0.05% level 
(P<0.0005). The study provides the first potential evidence that Brahmisohaladi Sirolepa may be 
capable of modifying the core social and cognitive defects associated with ASD. 
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INTRODUCTION
ASD is one among the most enigmatic forms 
of disability mainly due to the socio behavioural 
attributes of the diseased. ASD includes Autism, 
Asperger syndrome, Childhood Disintegrative 
disorder & Pervasive developmental disorders not 
otherwise specified.[1] It involves severe difficulties in 
basic aspects of social behaviour such as eye contact, 
facial expression, unusual gestures, diminished 
responsiveness, pragmatic deficits, neologism, lack of 
emotions in speech, unusual response to sensory 
stimuli etc.[2] This group of neuropsychiatric 
disorders show specific delay & deviance in social, 
communicative & cognitive development with 
developmental regression, absence of protodeclara-
tive pointing, abnormal reaction to environmental 
stimuli, abnormal social interests, absence of 
symbolic play and so on.  
Global prevalence of ASD ranges from 0.07% 
to 1.8%.[3,4] A population study conducted in nine 
different centres over five zones in India was 
concluded with a prevalence rate of 1.2%.[5] Male sex 
and upper socio economic group had a higher risk of 
Autism when compared to lower socio economic 
group.[6] Recent decades have witness an alarming 
increase in prevalence of this disorder all over the 
world.  
  Although the exact cause of ASD is still not 
known, the main findings emphasize the role of 
genetic and environmental factors in the 
development of autistic behaviour.[7] Environmental 
factors are also likely to interact with the genetic 
profile and cause aberrant change in brain growth, 
neuronal development and functional connectivity.[8]  
Pharmacological therapy in ASD is limited to 
Respiridone and Aripiprazole. [9] But they are 
approved by FDA only for managing the irritability 
associated with the disorder. [10] Selective serotonin 
receptive inhibitors (SSRIs) are prescribed for the 
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treatment of conditions often co morbid with ASD 
such as depression, anxiety and obsessive compulsive 
behaviour. [11] But the researchers in the field were 
unable to come up with a statistical evidence to prove 
its efficacy against the emerging evidence of harm. [12]  
Early intervention of ASD with 
communication DEALL programme (Developmental 
Eclectic Approach to Language Learning) by 
providing intensive stimulation for 3-4 hrs per day 
for 5 days per week over an academic year by a team 
of speech language pathologists, occupational 
therapists, developmental psychologists and special 
educators 1: 4 staff student ratio has come up with 
statistically significant increase in developmental 
domains & autism severity as measured by CARS. [13] 
Only behaviour therapies have proven their efficacy 
in managing the socio behavioural attributes of ASD. 
[14,15] But they are very time consuming and it 
demands one to one training for prolonged duration 
for 50 to 60 hours per week under the personal 
guidance of expertise .This type of ideal behaviour 
therapy is setting out of reach for more than 80% of 
ASD population.  
 The multiple developmental and behavioral 
problems associated with ASD necessitate 
multidisciplinary care, coordination of services, and 
advocacy for individuals and their families. Early and 
sustained intervention with the help of multiple 
treatment modalities is always indicated.[16,17] Here 
lies the importance of highly economical, child 
friendly and easily implementable Sirolepa with no 
drug interactions or side effects. 
 Ayurveda has viewed ASD as a behavioural 
abnormality with its roots embedded in the defective 
neuropsychological platform and derangement in 
digestive and metabolic system. Unmada is a 
spectrum of neuropsychological disorders affecting 
the smooth functioning of Manas (mind), Budhi 
(intellect), Samnja (consciousness), Jnana (know-
ledge), Smriti (memory), Bhakthi (desire), Seela 
(manners), Chesta (behaviour) and Achara 
(conduct).[18] The acquisition of knowledge (Jnanot-
pathy), one among the important functions of Manas 
is disturbed in Unmada. Jnanotpathy happens only 
when Manas is in tune with Atma (soul), Indriya 
(sense organ), Indriyartha (objects).[19] So even if 
there is no defect in hearing capacity, they are unable 
to comprehend the speech and act accordingly. They 
can appreciate the tone, pitch and modulation of 
sound, but in no way can help in language 
reception.[20] Similar is the condition with other 
senses also. Inability in sharing of emotions like joy 
or sorrow, feeling of empathy, emotional reciprocity 
etc point towards the involvement of Manas in the 
pathology of disease. The concept of genetic defects 
(Beeja dushti), antenatal psychological stress, non 
congenial dietetics (Virudha ahara) disturbing the 
metabolism (gut brain axis), defective parental 
psychological back ground (parental genetic makeup) 
and faulty child rearing system (refrigerated 
parentage, neglected childhood, monitor addiction) 
have the key role in the etiopathology of Unmada and 
ASD.[21] Uneven development of functional areas of 
brain, unstable neurotransmitter level controlling the 
brain functions etc. have been incorporated in 
framing the treatment outline.  
 The present study empirically analysis the 
efficacy of Sirolepa with Brahmisohaladi in managing 
the sociobehavioural attributes of ASD. Application of 
medicated paste on shaved scalp form the base of 
Sirolepa. Balasohaladi Sirolepa has its classical 
reference in Arogyakalpadruma in the context of 
Unmada. [22] Brahmisohaladi Sirolepa is an alteration 
in the ingredients of Balasohaladi Sirolepa with a 
view to address the behavioural attributes of ASD, 
due to the functional derangement of the Pitha. Bala 
leaves in Balasohaladi Sirolepa were replaced with 
fresh Brahmi leaves having more Pithasamana and 
Medhya property, forming Brahmisohaladi Sirolepa. 
MATERIALS AND METHODS 
Contents of Brahmisohaladi Sirolepa 
1. Fresh whole plant of Brahmi – 50g  
2. Fresh whole plant of Sohala – 50g  
3. Powder of Mustha - 12g  
4. Powder of Jeeraka - 12g  
5. Panchagandha churna (Hreebera, Sevya, Kushta, 
Yashti, Rakthachandana)- 60g  
6. Navaneetha ( salt less butter ) – 48g  
7. Cow’s milk – 50 ml (as required to make a 
smooth paste) 
Table 1: Chemical Constituents of the ingredients of Brahmisohaladi Sirolepa 
S.No. Sanskrit/English name Botanical name Part used Chemical Constituents [23] 
1 Brahmi Bacopa monnieri Whole plant Brahmine, Herpestine, Alanine, 
Hersaponin, Monnierin, Octacosane, 
Bacogenins 
2 Sohala/ Common  
purslane  
Portulaca oleracea 
Linn.  
Whole plant Norepinephrine, Oleracein, 
Hesperidin, Caffeic acid , Alanine, 
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Catechol[24] 
3 Musta / Nut grass Cyperus ritundus 
Linn 
Root CyperenI& II, Cyperenone, Cyperol, 
Sugenol, β-Sitosterol, Mustakone. [25,26] 
4 Jeeraka/ Cumin seeds  Cuminum cyminum 
Linn  
Seeds Cuminin, Diacyl glycerol, Imperatorin, 
Apigenin, Cuminaldehyde. 
5 Hreebera Plectranthus 
vettiveroides 
Whole plant Androstan, Spathulenol, Z-valerenyl 
acetate, myrtenol,1naphthalenol 
6 Sevya / Cuscus grass Vetiveria zizanoides 
Linn. 
 Eugenol, Vetiverol, Zizanol, 
Khusimene, Sesquiterpenes[27] 
7 Kushta/ Costus root  Saussarea lappa Root Costol, Costunolide, Sitosterol 
8 Yashtimadhu/ 
Liquorice root 
Glycyrrhiza glabra 
Linn. 
Root Glycyrrhizin, Liquirtin, Glabrene, 
Isoliquiritogenin[28,29] 
9 Rakta chandan/ 
Red sandal wood  
Pterocarpus 
santalinus Linn. 
Heart wood  Pterocarpol, Santalin A,B, Lapenediol 
Brahmisohaladi Sirolepa –  
Preparation and application 
The fresh whole plant of Brahmi and Sohala 
were taken in the mentioned quantity and washed 
well and made in to a paste without adding water. To 
this paste, 60 gram of Panchagandha choorna, 12 
gram each of Mustha and Jeeraka were added. The 
mixture was made in to paste by adding butter and 
required amount of milk. An earthen vessel was used 
to mix the ingredients. The medicinal paste was 
rubbed well in that earthen vessel for about 5 
minutes. After that the medicinal paste with thick 
consistency was obtained. Brahmisohaladi Sirolepa 
was applied all over the scalp in anticlockwise 
pattern ensuring a uniform thickness of 0.5cm. The 
duration of Sirolepa was one hour on the first day. It 
was advised to increase the time period 30 minutes 
per day till 14th day .The maximum time of keeping 
the Sirolepa on scalp was 7.30 hour on day 14. The 
same time period repeated on day 15. From day 16 
onwards, the duration gradually decreased by half 
hour. Thus by the 28th day the time period was 
reduced to 1 hour. It was advised to do the Sirolepa 
after 8 am and finish before 6pm. Scalp was cleaned 
with a dry cloth and advised to take bath in water 
boiled with leaves of Sida retusa and Panchagandha 
choorna.  
Methodology 
The study was conducted at Dept. of 
Kaumarabhrithya, Government Ayurveda College, 
Thiruvananthapuram in ASD children between 3 and 
12 years selected from the outpatient cases. Those 
children satisfying the DSM V (Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition) 
criteria and having a CARS (Childhood Autism Rating 
Scale) score above 30 was selected for the study.[30,31] 
Children having intractable seizures and recurrent 
upper respiratory tract infections were excluded 
from the study for fear of drug interactions and 
chances of exacerbation of respiratory infection 
during the treatment phase. Evaluation of the cases 
was done with Internationally accepted assessment 
tools like CARS and ATEC (Autism Treatment 
Evaluation Checklist).[32] Evaluation of the efficacy of 
the treatment in the different aspects of ASD like 
speech and language, sociability, sensory /cognitive 
awareness and behavioural domains could be made 
possible by subscales of ATEC. Blinded evaluation of 
cases before and after the treatment duration of 28 
days was done by a psychologist. 
Ethical Consideration 
Ethical considerations were satisfied 
throughout the study. The treatment used in the 
study was time tested and safe as per the 
professional experience of the department. The 
parents of the children were explained about the 
details of the study and an informed consent was 
obtained from them before recruiting him/her into 
the study. The parents were allowed to withdraw 
their children from the study at any time at their will. 
The information about the patients was kept 
confidential. 
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Statistics 
Table 2: Pre-post evaluation with CARS and ATEC 
  CARS   ATEC   
Case No Before Rx After Rx Before Rx After Rx 
1 38 36 98 84 
2 37 34.5 95 79 
3 37 34 84 70 
4 34.5 31 88 72 
5 44 39 122 103 
6 30.5 27 74 60 
7 32 29.5 79 65 
8 39 35.5 104 83 
9 35.5 32 96 81 
10 40 35.5 112 94 
11 33 29 83 69 
12 38 34 94 76 
13 42 36.5 117 98 
14 46 40.5 134 104 
15 32 29 84 69 
16 40 35.5 106 88 
17 35 31.5 89 71 
18 38 33.5 92 74 
19 31 28.5 68 55 
20 44 39.5 126 103 
21 32 26.5 72 61 
The Paired Samples t Test compares two means that are from the same cases. The two means typically 
represent two different times (e.g., pre-test and post-test with an intervention between the two time points. 
The purpose of the test is to determine whether there is statistical evidence that the mean difference between 
paired observations on a particular outcome is significantly different from zero. Statistical analysis of the pre 
and post test results revealed a highly significant response in the reduction of severity of ASD in CARS (p 0.000) 
and ATEC scores (p 0.000). Hyperactivity, temper tantrums, repetitive movements, shouting/screaming, 
oversensitivity to sound and sleep issues showed remarkable response in clinically notable level.  
Table 3: Data and test of significance (paired t test) on effectiveness of treatment 
Variable Time Mean N Std. Deviation T df p 
CARS BT 37.071 21 4.5312 
16.686 20 .000 
AT 33.238 21 4.0485 
ATEC BT 96.05 21 18.178 
18.921 20 .000 
AT 79.00 21 14.789 
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Graph 1: Efficacy of treatment in CARS  
 
Graph 2: Efficacy of treatment in ATEC 
 
DISCUSSION 
Children satisfying the inclusion criteria of 
CARS 30 were exhibiting derangements in the 
functional level of both Vata and Pitha with a marked 
predominance of Pitha attributes like irritability, 
temper tantrums, inflicting self injury and hurting 
others, hyperactivity, excessive thirst and appetite, 
insomnia, affinity towards playing with water and 
desire for cool climatic conditions. As the functional 
derangements in the activity of brain was evident, 
Vathapitha samana treatment was opted to be done 
at Siras (Rogadhishtana). Even if the treatment 
principles of Unmada comprises of many procedure 
based therapies and detoxification procedures 
including digestive correction , these special kids 
would rarely cooperate with these therapies at this 
stage of irritability and hyper activity. So a child 
friendly procedure like Sirolepa was selected based 
on the classical references. Clinical results observed 
with Brahmi Sirolepa in ASD cases was the base for 
replacing Bala leaves of Balasohaladi Sirolepa with 
Brahmi. Moreover Brahmi is known to have more 
Rasayana property with Medhya prabhava. Paste of 
fresh leaves of Brahmi was found to have more Pitha 
Samana property. All other drugs in the formulation 
were having Vatapitha samana property and could be 
made into a smooth paste with milk and butter. 
Covering the Sirolepa with fresh lotus leaves (like a 
medicated cap) ensured the retention of the cooling 
effect of the Sirolepa without drying for longer 
duration. It was noted that that there was not a single 
drop our during the treatment plan. Two children 
had one episode each of rhinitis which subsided 
without medical management within a few days. 
Sirolepa was restricted during this period. 
 The results showed that there is statistically 
significant (p 0.000) improvement in the severity of 
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Autism. The period of intervention was very short 
(28 days). So we couldn’t find any remarkable change 
in language skills. 
CONCLUSION 
 Symptoms of ASD attributed to Pitha 
derangements showed statistically significant (p 
0.000) changes after the treatment. Temper 
tantrums, irritability, insomnia, self injurious 
behaviour and hyperactivity reduced considerably in 
the CARS and ATEC score sheets. During and after the 
intervention the children were more cooperative for 
speech and behavioural intervention which reflected 
in the social behaviour and language acquisition 
skills. The study drug, Brahmisohaladi Sirolepa, is 
only one among the vast treatment schedules 
elaborated for managing Unmada. Clinical expertise 
in the field has shown the Ayurveda intervention has 
the potential to revert the pathology of ASD bringing 
back to the normal life.  
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